Clinical Trial Results:
A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participated in Study SPD503-315 or SPD503-316
Summary
|
|
EudraCT number |
2011-004668-31 |
Trial protocol |
GB DE SE AT ES IE BE IT NL PL |
Global end of trial date |
15 Sep 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
28 Jul 2016
|
First version publication date |
28 Jul 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
SPD503-318
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01500694 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Shire Pharmaceutical Development Ltd.
|
||
Sponsor organisation address |
Hampshire International Business Park Chineham, Basingstoke, Hampshire, United Kingdom, RG24 8EP
|
||
Public contact |
Study Physician, Shire, +1 866-842-5335,
|
||
Scientific contact |
Study Physician, Shire, +1 866-842-5335,
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
15 Sep 2015
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Sep 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of this study was to evaluate the long-term safety and tolerability of SPD503.
|
||
Protection of trial subjects |
This study was conducted in accordance with International Conference on Harmonisation (ICH) of Good Clinical Practice (GCP), the principles of the Declaration of Helsinki, and other applicable local ethical and legal requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
20 Mar 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 2
|
||
Country: Number of subjects enrolled |
Belgium: 10
|
||
Country: Number of subjects enrolled |
France: 6
|
||
Country: Number of subjects enrolled |
Germany: 53
|
||
Country: Number of subjects enrolled |
Italy: 20
|
||
Country: Number of subjects enrolled |
Netherlands: 9
|
||
Country: Number of subjects enrolled |
Poland: 19
|
||
Country: Number of subjects enrolled |
Romania: 7
|
||
Country: Number of subjects enrolled |
Spain: 36
|
||
Country: Number of subjects enrolled |
Ukraine: 41
|
||
Country: Number of subjects enrolled |
United Kingdom: 12
|
||
Worldwide total number of subjects |
215
|
||
EEA total number of subjects |
174
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
110
|
||
Adolescents (12-17 years) |
100
|
||
Adults (18-64 years) |
5
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||||||||
Recruitment details |
The study was conducted at 52 sites in 11 countries in Europe: Austria, Belgium, France, Germany, Italy, The Netherlands, Poland, Romania, Spain, Ukraine, and United Kingdom. | |||||||||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||||||||
Screening details |
Of 218 subjects screened, 215 subjects were enrolled:131 subjects aged 6-12 years and 84 subjects aged 13-18 years. Among them 214 subjects received treatment, of which 133 subjects completed the study. The first subject’s consent was obtained on 20 March 2012 and the last subject assessment took place on 15 September 2015. | |||||||||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||||||||
Arm title
|
SPD503 (6-12 years) | |||||||||||||||||||||||||||||||||
Arm description |
Subjects aged 6-12 years received extended-release guanfacine hydrochloride (SPD503) one tablet (1 x 1 milligram [mg] or 2 mg or 3 mg or 4mg) or two tablets (1 x 2+3 mg or 1 x 2+4 mg, 1 x 3+4 mg) once daily for up to 2 years. | |||||||||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Extended-release guanfacine hydrochloride
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
SPD503
|
|||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
Subjects received extended-release guanfacine hydrochloride (SPD503) one tablet (1-4mg) or two tablets (5-7 mg) once daily.
|
|||||||||||||||||||||||||||||||||
Arm title
|
SPD503 (13-18 years) | |||||||||||||||||||||||||||||||||
Arm description |
Subjects aged 13-18 years received extended-release Guanfacine hydrochloride (SPD503) one tablet (1 x 1 mg or 2 mg or 3 mg or 4mg) or two tablets (1 x 2+3 mg or 1 x 2+4 mg, 1 x 3+4 mg) once daily for up to 2 years. | |||||||||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Extended-release guanfacine hydrochloride
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
SPD503
|
|||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
Subjects received extended-release guanfacine hydrochloride (SPD503) one tablet (1-4mg) or two tablets (5-7 mg) once daily.
|
|||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: Not all the subjects reported in the baseline period were treated with the study drug, that is the reason the worldwide number enrolled is not the same as the baseline period. |
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
SPD503 (6-12 years)
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects aged 6-12 years received extended-release guanfacine hydrochloride (SPD503) one tablet (1 x 1 milligram [mg] or 2 mg or 3 mg or 4mg) or two tablets (1 x 2+3 mg or 1 x 2+4 mg, 1 x 3+4 mg) once daily for up to 2 years. | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
SPD503 (13-18 years)
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects aged 13-18 years received extended-release Guanfacine hydrochloride (SPD503) one tablet (1 x 1 mg or 2 mg or 3 mg or 4mg) or two tablets (1 x 2+3 mg or 1 x 2+4 mg, 1 x 3+4 mg) once daily for up to 2 years. | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
SPD503 (6-12 years)
|
||
Reporting group description |
Subjects aged 6-12 years received extended-release guanfacine hydrochloride (SPD503) one tablet (1 x 1 milligram [mg] or 2 mg or 3 mg or 4mg) or two tablets (1 x 2+3 mg or 1 x 2+4 mg, 1 x 3+4 mg) once daily for up to 2 years. | ||
Reporting group title |
SPD503 (13-18 years)
|
||
Reporting group description |
Subjects aged 13-18 years received extended-release Guanfacine hydrochloride (SPD503) one tablet (1 x 1 mg or 2 mg or 3 mg or 4mg) or two tablets (1 x 2+3 mg or 1 x 2+4 mg, 1 x 3+4 mg) once daily for up to 2 years. |
|
|||||||||||||||||||
End point title |
Change from Baseline in Mean Systolic Blood Pressure at Final Assessment [1] | ||||||||||||||||||
End point description |
Systolic Blood pressure was measured at supine and standing position and mean supine systolic blood pressure was reported here. Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ Early Terminatino [ET]/Day 714). Safety Analysis Set includes all enrolled subjects who took at least 1 dose of SPD503. Here, n = number of subjects analysed for the specific categories for each arm respectively.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive analysis were performed, inferential statistics were not performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Mean Diastolic Blood Pressure at Final Assessment [2] | ||||||||||||||||||
End point description |
Diastolic Blood pressure was measured at supine and standing position and mean supine diastolic blood pressure was reported here. Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714). Safety Analysis Set includes all enrolled subjects who took at least 1 dose of SPD503. Here, n = number of subjects analysed for the specific categories for each arm respectively.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
||||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive analysis were performed, inferential statistics were not performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Mean Supine Pulse at Final Assessment [3] | ||||||||||||||||||
End point description |
Pulse was measured at supine and standing position and mean supine pulse was reported here. Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714). Safety Analysis Set includes all enrolled subjects who took at least 1 dose of SPD503. Here, n = number of subjects analysed for the specific categories for each arm respectively.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
||||||||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive analysis were performed, inferential statistics were not performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Mean Height at Final Assessment [4] | ||||||||||||||||||
End point description |
Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714). Safety Analysis Set included all enrolled subjects who took at least 1 dose of SPD503. Here, n = number of subjects analysed for the specific categories for each arm respectively.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
||||||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive analysis were performed, inferential statistics were not performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Mean Weight at Final Assessment [5] | ||||||||||||||||||
End point description |
Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714). Safety Analysis Set included all enrolled subjects who took at least 1 dose of SPD503. Here, n = number of subjects analysed for the specific categories for each arm respectively.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
||||||||||||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive analysis were performed, inferential statistics were not performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Electrocardiogram Result (QRS interval) at Final Assessment [6] | ||||||||||||||||||
End point description |
Safety Analysis Set included all enrolled subjects who took at least 1 dose of SPD503. Here, n = number of subjects analysed for the specific categories for each arm respectively. Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714).
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
||||||||||||||||||
Notes [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive analysis were performed, inferential statistics were not performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Electrocardiogram Result (QT interval) at Final Assessment [7] | ||||||||||||||||||
End point description |
Safety Analysis Set included all enrolled subjects who took at least 1 dose of SPD503. Here, n = number of subjects analysed for the specific categories (Visit 19/ET/Day 714). Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication. Here, n = number of subjects analysed for the specific categories for each arm respectively.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
||||||||||||||||||
Notes [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive analysis were performed, inferential statistics were not performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Columbia-Suicide Severity Rating Scale (C-SSRS) [8] | |||||||||||||||||||||
End point description |
C-SSRS is a semi-structured interview that captures the occurrence, severity and frequency of suicide-related thoughts and behaviours during the assessment period.There is a maximum of 19 items to be completed: 7 that are required, 10 potential additional items if there is a positive response to a required item and 2 items for suicide/suicide behaviour present during the interview. Final Assessment is last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714). Safety Analysis Set included all enrolled subjects who took at least 1 dose of SPD503 with number of subjects evaluable for this end point only. One subject aged 6-12 years responded "yes" to the suicidal ideation category of "wish to be dead" while not on treatment (at the end of treatment visit, after his last dose).
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
|||||||||||||||||||||
Notes [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive analysis were performed, inferential statistics were not performed. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Attention deficit and Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV)- Total Score at Final Assessment | ||||||||||||||||||
End point description |
ADHD-RS-IV was developed to measure the behaviours of children with ADHD with 18 items. Each item is scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items may be grouped into 2 sub-scales: hyperactivity/impulsivity (even numbered items 2-18) and inattentiveness (odd numbered items 1-17) with possible score range from 0 (no symptoms) to 27 (most severe symptoms). The ADHD-RS-IV possible total scores range from 0 (no symptoms) to 54 (most severe symptoms). Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714). Full Analysis Set included enrolled subjects who took at least 1 dose of SPD503, excluding subjects from site 403. Here, n = number of subjects analysed for the specific categories for each arm respectively.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of subjects assessed with Clinical Global Impression - Severity of Illness (CGI-S) Scale | ||||||||||||||||||||||||
End point description |
The CGI-S evaluate each subject's severity and improvement over time. The severity of a subject’s condition is rated on a 7-point scale ranging from 1 to 7. The scale measures 0= Not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill (BL-MI), 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill subjects. Final Assessment is the last valid assessment obtained after Baseline (Visit 2/Day 0) whilst on investigational product and before first dose taper medication (Visit 19/ET/Day 714). Full Analysis Set included enrolled subjects who took at least 1 dose of SPD503, excluding subjects from site 403. Here, n = number of subjects analysed for the specific categories for each arm respectively.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Baseline (Day 0) and Final Assessment (last non missing data/up to Day 714)
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From the start of the study drug administration up to 10 days after the last dose of study drug administration
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
12.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
SPD503 (6-12 years )
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects aged 6-12 years received extended-release guanfacine hydrochloride (SPD503) one tablet (1 x 1 mg or 2 mg or 3 mg or 4mg) or two tablets (1 x 2+3 mg or 1 x 2+4 mg, 1 x 3+4 mg) once daily for up to 2 years. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
SPD503 (13-18 years )
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects aged 13-18 years received extended-release guanfacine hydrochloride (SPD503) one tablet (1 x 1 mg or 2 mg or 3 mg or 4mg) or two tablets (1 x 2+3 mg or 1 x 2+4 mg, 1 x 3+4 mg) once daily for up to 2 years. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
15 Nov 2011 |
-It was clarified that adolescent subjects aged greater than equal (>=) 13 years enrolling from Study SPD503-316 (2010-018579-12) must have completed 13 weeks of double-blind treatment in study SPD503-316 (2010-018579-12).
-Sentences that limited dose reduction to only 1 reduction during the study were removed. |
||
10 Jan 2012 |
-The primary and secondary objectives were revised.
-The rationale and study design were clarified to align with the revised primary and secondary objectives.
-Text was added to clarify visit windows for Visits 18 and 19 (Schedule of Assessments).
-The number of days between Visit 18 and Visit 19 was revised to 98 days to be consistent with the 14 weeks between these visits.
-The total days listed for Visits 20 and 21 was revised.
-Urine pregnancy test for all female subjects of childbearing potential at Visit 6 and Visits 10-18 was added.
-Bands were removed from hematology assessments.
-The days provided in Table 6 (dose tapering schedule) were revised from Days 700-714 to Days 714-728. |
||
29 Jan 2013 |
-Serious adverse events (SAE), pregnancy, and product quality complaint reporting language was updated.
-The number of expected sites was updated.
-It was clarified when the screening visit for this study could occur in relation to the antecedent study.
-Inclusion criteria were revised for subjects enrolling from antecedent study SPD503-315 (2009-018161-12) and SPD503-316 (2010-018579-12).
-Wash period of 30 days was deleted from Investigational compounds.
-A minimum washout” was deleted from Investigational compounds to be consistent with the rest of the table.
-With the exception of investigational product taken in Study SPD503-315 (2009-018161-12) which only required a 7-day washout prior to the baseline visit (Visit 2)” was deleted from alpha (α) 2-adrenergic agonists.
-Electrocardiogram (ECGs) was deleted from screening visit.
-Information on the planned data cut for regulatory authority submission purposes was added. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |